OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al.
JAMA (2021) Vol. 326, Iss. 23, pp. 2375-2375
Open Access | Times Cited: 116
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, et al.
JAMA (2021) Vol. 326, Iss. 23, pp. 2375-2375
Open Access | Times Cited: 116
Showing 101-125 of 116 citing articles:
Adalimumab Therapeutic Drug Monitoring Improves Treatment Outcome in Patients with Psoriasis
Afsáneh Alavi, Edward V. Loftus
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 9, pp. 1625-1628
Open Access | Times Cited: 1
Afsáneh Alavi, Edward V. Loftus
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 9, pp. 1625-1628
Open Access | Times Cited: 1
Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives
E. H. Smeijsters, Kim C. M. van der Elst, Amy Visch, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1477-1477
Open Access | Times Cited: 1
E. H. Smeijsters, Kim C. M. van der Elst, Amy Visch, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1477-1477
Open Access | Times Cited: 1
POS0630 ANTIDRUG ANTIBODIES ARE NEGATIVELY ASSOCIATED WITH RESPONSE TO BIOLOGICAL DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF THE ABIRISK STUDY
S. Bitoun, Signe Hässler, David Ternant, et al.
Annals of the Rheumatic Diseases (2023), pp. 590.2-590
Open Access | Times Cited: 1
S. Bitoun, Signe Hässler, David Ternant, et al.
Annals of the Rheumatic Diseases (2023), pp. 590.2-590
Open Access | Times Cited: 1
Safety Summary of Pediatric Inflammatory Bowel Disease Therapies
Xiaoyi Zhang, Joel R. Rosh
Gastroenterology Clinics of North America (2023) Vol. 52, Iss. 3, pp. 535-548
Closed Access | Times Cited: 1
Xiaoyi Zhang, Joel R. Rosh
Gastroenterology Clinics of North America (2023) Vol. 52, Iss. 3, pp. 535-548
Closed Access | Times Cited: 1
The role of therapeutic drug monitoring in the management of inflammatory bowel disease
Devendra Desai, Vikram Dharap
Gastroenterology Hepatology and Endoscopy Practice (2023) Vol. 3, Iss. 3, pp. 72-72
Closed Access | Times Cited: 1
Devendra Desai, Vikram Dharap
Gastroenterology Hepatology and Endoscopy Practice (2023) Vol. 3, Iss. 3, pp. 72-72
Closed Access | Times Cited: 1
Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels
Joel Thunberg, Olle Grännö, Daniel Bergemalm, et al.
Scandinavian Journal of Gastroenterology (2023) Vol. 59, Iss. 2, pp. 150-155
Open Access | Times Cited: 1
Joel Thunberg, Olle Grännö, Daniel Bergemalm, et al.
Scandinavian Journal of Gastroenterology (2023) Vol. 59, Iss. 2, pp. 150-155
Open Access | Times Cited: 1
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases—Reply
Silje Watterdal Syversen, Jørgen Jahnsen, Espen A. Haavardsholm
JAMA (2022) Vol. 327, Iss. 15, pp. 1506-1506
Closed Access | Times Cited: 2
Silje Watterdal Syversen, Jørgen Jahnsen, Espen A. Haavardsholm
JAMA (2022) Vol. 327, Iss. 15, pp. 1506-1506
Closed Access | Times Cited: 2
Intérêt des dosages pharmacologiques d’immunosuppresseurs et immunomodulateurs dans la prise en charge des maladies autoimmunes
Sarah Djabarouti, Pierre Mora, M. Lahouati, et al.
La Revue de Médecine Interne (2022) Vol. 43, Iss. 7, pp. 412-418
Closed Access | Times Cited: 2
Sarah Djabarouti, Pierre Mora, M. Lahouati, et al.
La Revue de Médecine Interne (2022) Vol. 43, Iss. 7, pp. 412-418
Closed Access | Times Cited: 2
Inappropriate Evaluation of Effect Modifications Based on Categorical Outcomes: A Systematic Review of Randomized Controlled Trials
Akihiro Shiroshita, Norio Yamamoto, Natsumi Saka, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 22, pp. 15262-15262
Open Access | Times Cited: 1
Akihiro Shiroshita, Norio Yamamoto, Natsumi Saka, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 22, pp. 15262-15262
Open Access | Times Cited: 1
The Future of Therapeutic Drug Monitoring in Inflammatory Bowel Disease: An Emphasis on the Essential Ingredients
Antonius T. Otten, Gerard Dijkstra, Marijn C. Visschedijk, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 2, pp. 318-319
Closed Access
Antonius T. Otten, Gerard Dijkstra, Marijn C. Visschedijk, et al.
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 2, pp. 318-319
Closed Access
Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease
Lidia Díaz, Carles Iniesta Navalón, Rosa Gómez Espín, et al.
Gastroenterología y Hepatología (English Edition) (2023) Vol. 46, Iss. 7, pp. 504-511
Closed Access
Lidia Díaz, Carles Iniesta Navalón, Rosa Gómez Espín, et al.
Gastroenterología y Hepatología (English Edition) (2023) Vol. 46, Iss. 7, pp. 504-511
Closed Access
Evaluation of Proactive Therapeutic Drug Monitoring Application in Infliximab Users in Ulcerative Colitis
Gabriela Maria Henz Giovelli, Ornella Sari Cassol, Márcio Lubini, et al.
Journal of Coloproctology (2023) Vol. 43, Iss. 04, pp. e286-e291
Open Access
Gabriela Maria Henz Giovelli, Ornella Sari Cassol, Márcio Lubini, et al.
Journal of Coloproctology (2023) Vol. 43, Iss. 04, pp. e286-e291
Open Access
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases
Eugen Javor, Goran Hauser, Marko Skelin
JAMA (2022) Vol. 327, Iss. 15, pp. 1505-1505
Closed Access
Eugen Javor, Goran Hauser, Marko Skelin
JAMA (2022) Vol. 327, Iss. 15, pp. 1505-1505
Closed Access
Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases
Niels Vande Casteele
JAMA (2022) Vol. 327, Iss. 15, pp. 1506-1506
Closed Access
Niels Vande Casteele
JAMA (2022) Vol. 327, Iss. 15, pp. 1506-1506
Closed Access
Les anticorps anti-biomédicament sont négativement associés à la réponse au traitement par anti-TNF monoclonaux et anti-IL-6 récepteur dans la polyarthrite rhumatoïde : les résultats de l’étude ABIRISK
Samuel Bitoun, Signe Hässler, Natacha Szely, et al.
Revue du Rhumatisme (2022) Vol. 89, pp. A21-A22
Closed Access
Samuel Bitoun, Signe Hässler, Natacha Szely, et al.
Revue du Rhumatisme (2022) Vol. 89, pp. A21-A22
Closed Access
Intérêt du dosage des anticorps antimédicaments dans les rhumatismes inflammatoires
Sophia Ascione, Camille Blandin
Elsevier eBooks (2022), pp. 179-189
Closed Access
Sophia Ascione, Camille Blandin
Elsevier eBooks (2022), pp. 179-189
Closed Access
